Allarity Therapeutics vs CytoMed Therapeutics
ALLR and GDTC side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ALLR and GDTC compare
CytoMed Therapeutics scores higher on the StockData Score (4 against 1 for Allarity Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ALLR | GDTC |
|---|---|---|
| Size and price | ||
| Market cap | $13.4M | – |
| Share price | $0.841 | $0.783 |
| Change, 1 year | −28.7% | −60.1% |
| Beta (5Y) | 1.46 | −0.42 |
| Employees | 8 | 5 |
| StockData Score | ||
| Total score | 1 | 4 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 1 (better) |
| Performance score | 0 | 1 (better) |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 3.8× | – |
| Growth | ||
| Revenue growth (TTM) | – | 367% |
| Profitability | ||
| Net margin | – | −1227% |
| FCF margin | – | −1336% |
| Return on equity | −157% | −51.3% (better) |
| Return on invested capital | −957% | – |
| Financial health | ||
| Debt / equity | 5.90 | 0.06 (better) |
| Interest coverage | −10.1× | – |
| Current ratio | 1.11 | 5.17 (better) |
| Altman Z-score | −6.65 | – |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Buyback yield | 6.6% | – |
| Shareholder yield | 6.6% | – |
| Ownership | ||
| Held by institutions | 8.1% | 0.10% |
| Held by insiders | 6.3% | 25.9% |
| Insider net buying, 12 months | – | $729K |
| Short interest, % of float | 1.5% | – |
Go deeper
- ALLR stock overview
- ALLR income statement
- ALLR valuation and score
- GDTC stock overview
- GDTC income statement
- GDTC valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.